OvaScience (NASDAQ:OVAS) Getting Somewhat Favorable Media Coverage, Report Finds

News headlines about OvaScience (NASDAQ:OVAS) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.3454455664725 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news articles that may have impacted Accern’s scoring:

Several equities analysts have recently commented on OVAS shares. Zacks Investment Research lowered OvaScience from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of OvaScience in a research note on Monday, November 6th.

Shares of OvaScience (NASDAQ:OVAS) traded up $0.07 during trading on Tuesday, hitting $1.18. The stock had a trading volume of 2,501,000 shares, compared to its average volume of 1,702,367. The stock has a market capitalization of $41.78, a price-to-earnings ratio of -0.64 and a beta of 3.73. OvaScience has a 1 year low of $1.08 and a 1 year high of $2.05.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.15. OvaScience had a negative return on equity of 68.71% and a negative net margin of 20,090.13%. equities analysts forecast that OvaScience will post -1.48 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://baseballnewssource.com/markets/ovascience-ovas-getting-somewhat-positive-press-coverage-report-shows/1820905.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.